Survodutide

Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist being developed by Boehringer Ingelheim for treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH/NASH). The dual agonist mechanism combines GLP-1's appetite suppression and glucose-lowering effects with glucagon's ability to increase energy expenditure and promote hepatic fat oxidation. This combination addresses metabolic disease from multiple angles, potentially offering advantages over GLP-1-only agonists. Clinical trials have demonstrated significant weight loss approaching 20% of body weight in some studies, along with improvements in liver fat and markers of liver inflammation and fibrosis. The glucagon component specifically targets hepatic metabolism, making survodutide particularly relevant for fatty liver disease. Phase 3 clinical trials are ongoing for multiple metabolic indications. Survodutide represents the next generation of incretin-based therapies designed to provide comprehensive metabolic benefits beyond glucose control and weight loss.

Evidence is Phase 2 only; Phase 3 results are pending; gastrointestinal tolerability mirrors other incretin drugs; no approved indication yet; long-term safety (pancreatic, thyroid, cardiovascular) remains under study.

Survodutide (BI 456906) is an investigational once-weekly subcutaneous dual GLP-1/glucagon receptor agonist designed to combine glucagon-mediated energy expenditure with GLP-1-mediated appetite suppression; Phase 2 doses ranged up to 4.8 mg weekly.